Cantor Fitzgerald Maintains Overweight on VolitionRX, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kyle Mikson has maintained an Overweight rating on VolitionRX (AMEX:VNRX) but lowered the price target from $3 to $2.
August 16, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on VolitionRX but lowered the price target from $3 to $2.
The lowering of the price target by Cantor Fitzgerald could potentially lead to a decrease in the stock price of VolitionRX in the short term. However, the maintained Overweight rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100